n | Unadjusted HR (95% CI; p value) | p For trend | Adjusted HR* (95% CI; p value) | p For trend | |
---|---|---|---|---|---|
Mortality risk in the two separate supplement groups | |||||
All-cause mortality | |||||
Placebo | 163 | 1.00 | 0.46 | 1.00 | 0.89 |
0.2 mg folic acid | 45 | 1.21 (0.86 to 1.67; 0.28) | 1.27 (0.90 to 1.81; 0.17) | ||
5 mg folic acid | 33 | 0.79 (0.54 to 1.16; 0.23) | 0.87 (0.58 to 1.31; 0.52) | ||
Cardiovascular mortality | |||||
Placebo | 37 | 1.00 | 0.18 | 1.00 | 0.17 |
0.2 mg folic acid | 7 | 0.83 (0.37 to 1.86; 0.65) | 1.00 (0.44 to 2.27; 1.00) | ||
5 mg folic acid | 15 | 1.63 (0.89 to 2.97; 0.11) | 1.67 (0.86 to 3.26; 0.13) | ||
All cancer deaths | |||||
Placebo | 68 | 1.00 | 0.06 | 1.00 | 0.19 |
0.2 mg folic acid | 20 | 1.27 (0.77 to 2.09; 0.35) | 1.42 (0.84 to 2.39; 0.19) | ||
5 mg folic acid | 6 | 0.36 (0.16 to 0.83; 0.02) | 0.43 (0.19 to 1.00; 0.05) | ||
Breast cancer mortality | |||||
Placebo | 16 | 1.00 | 0.28 | 1.00 | 0.31 |
0.2 mg folic acid | 2 | 0.54 (0.12 to 2.34; 0.41) | 0.52 (0.12 to 2.31; 0.39) | ||
5 mg folic acid | 2 | 0.51 (0.12 to 2.23; 0.37) | 0.54 (0.12 to 2.41; 0.42) | ||
Mortality risk in the two supplement groups combined | |||||
All-cause mortality | |||||
Placebo | 163 | 1.00 | 1.00 | ||
Supplemented | 78 | 0.99 (0.75 to 1.30; 0.93) | 1.07 (0.80 to 1.43; 0.64) | ||
Cardiovascular mortality | |||||
Placebo | 37 | 1.00 | 1.00 | ||
Supplemented | 22 | 1.25 (0.74 to 2.11; 0.41) | 1.33 (0.75 to 2.35; 0.33) | ||
All cancer deaths | |||||
Placebo | 68 | 1.00 | 1.00 | ||
Supplemented | 26 | 0.80 (0.51 to 1.26; 0.34) | 0.91 (0.57 to 1.46; 0.70) | ||
Breast cancer mortality | |||||
Placebo | 16 | 1.00 | 1.00 | ||
Supplemented | 4 | 0.52 (0.18 to 1.57; 0.25) | 0.53 (0.17 to 1.62; 0.27) |
*Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.